COMPASS PATHWAYS ($CMPS) posted quarterly earnings results on Thursday, May 8th. The company reported earnings of -$0.44 per share, beating estimates of -$0.48 by $0.04. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $CMPS stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
COMPASS PATHWAYS Hedge Fund Activity
We have seen 53 institutional investors add shares of COMPASS PATHWAYS stock to their portfolio, and 59 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CITADEL ADVISORS LLC removed 4,308,900 shares (-79.6%) from their portfolio in Q4 2024, for an estimated $16,287,642
- RTW INVESTMENTS, LP added 3,098,987 shares (+inf%) to their portfolio in Q4 2024, for an estimated $11,714,170
- PARADIGM BIOCAPITAL ADVISORS LP removed 1,160,000 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $4,384,800
- LOGOS GLOBAL MANAGEMENT LP removed 1,159,030 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $4,381,133
- TANG CAPITAL MANAGEMENT LLC added 1,000,000 shares (+inf%) to their portfolio in Q4 2024, for an estimated $3,780,000
- SIO CAPITAL MANAGEMENT, LLC removed 914,639 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $3,457,335
- NANTAHALA CAPITAL MANAGEMENT, LLC added 800,000 shares (+400.0%) to their portfolio in Q4 2024, for an estimated $3,024,000
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
COMPASS PATHWAYS Analyst Ratings
Wall Street analysts have issued reports on $CMPS in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- H.C. Wainwright issued a "Buy" rating on 03/04/2025
- Canaccord Genuity issued a "Buy" rating on 11/11/2024
To track analyst ratings and price targets for COMPASS PATHWAYS, check out Quiver Quantitative's $CMPS forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
